For research use only
| Cat No. | ABC-TC0225 |
| Product Type | Rat Pancreas Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Rat |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pancreas |
| Product Code | DSL-6B-C2; DSL6B/C2 |
DSL-6B/C2 is a pancreatic ductal cell line derived from the DSL-6 transplantable acinar cell carcinoma.
The DSL-6B/C2 is a pancreatic ductal cell line derived from the DSL-6 transplantable acinar cell carcinoma of a 2-year-old male syngeneic Lewis rat. This cell line exhibits epithelial-like morphology with irregular glandular structures, prominent nucleoli and adherent culture properties, and is recommended to be cultured in Waymouth’s MB 752/1 Medium supplemented with 10% Fetal Bovine Serum (FBS). DSL-6B/C2 expresses mucin and duct cell markers. The cell line is highly tumorigenic and metastatic in syngeneic Lewis rats, forming solid and partially cystic tumors composed of mixed squamous, mucinous, and glandular areas. Metastases occur in ductal tissues. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | DSL-6B-C2; DSL6B/C2 |
| Species | Rat |
| Cat.No | ABC-TC0225 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pancreas |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Rat Pancreas Cancer Cell Lines |
DSL-6B/C2 cells serve as a syngeneic rat pancreatic ductal adenocarcinoma (PDAC) model to investigate tumor-stroma crosstalk and therapy resistance mechanisms. They enable in vitro chemotherapy screening and quantitative metastasis studies through analysis of TGF-β-mediated epithelial-mesenchymal transition (EMT). This system facilitates tumor microenvironment modeling in 3D organoids with intact stromal components and supports in vitro evaluation of potential therapeutic targets for aggressive pancreatic cancer.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
